New drug aims to curb impulsive behavior in opioid addiction
NCT ID NCT06628622
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage trial tests whether a daily tablet called BI 1356225 can improve impulse control in people with opioid use disorder who are already taking buprenorphine. About 60 participants will be randomly assigned to receive either the study drug or a placebo for 8 days. Researchers will measure impulsivity using computer tasks and questionnaires, and monitor safety closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Collaborative Neuroscience Research, LLC, Los Alamitos
Los Alamitos, California, 90720, United States
-
Hassman Research Institute-Marlton-66897
Marlton, New Jersey, 08053, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
iResearch Atlanta
Decatur, Georgia, 30030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1356225
What this could lead to
If it works, this could point toward a new treatment to help people with opioid addiction better control impulses and reduce risky behaviors.
What could go wrong
This is a very early Phase 1 trial with only 60 people, so it may not show a clear benefit. The study is also currently suspended, which could indicate challenges.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.